Search research articles
Contact Us
Filters
Showing results (81-90 of 88) with videos related to
Page
of 9
Sort By:
You have reached the last page of results.
This site can display upto 88 results.
Nature Cancer
|
February 5, 2022
A biobank of small cell lung cancer CDX models elucidates inter- and intratumoral phenotypic heterogeneity
Kathryn L Simpson, Ruth Stoney, Kristopher K Frese, et al.
Lancet (London, England)
|
August 3, 2024
Molecularly guided therapy versus chemotherapy after disease control in unfavourable cancer of unknown primary (CUPISCO): an open-label, randomised, phase 2 study
Alwin Krämer, Tilmann Bochtler, Chantal Pauli, et al.
European Journal of Cancer (Oxford, England : 1990)
|
October 10, 2022
Real-world outcomes with ipilimumab and nivolumab in advanced melanoma: a multicentre retrospective study
Patricio Serra-Bellver, Judith M Versluis, Honey K Oberoi, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
August 19, 2022
A Phase I Trial of CT900, a Novel α-Folate Receptor-Mediated Thymidylate Synthase Inhibitor, in Patients with Solid Tumors with Expansion Cohorts in Patients with High-Grade Serous Ovarian Cancer
Susana Banerjee, Vasiliki Michalarea, Joo Ern Ang, et al.
British Journal of Cancer
|
November 8, 2025
Experimental Cancer Medicine Centre (ECMC) network proposal for a consensus gene panel for pan-cancer sequencing: a Delphi methodology
Richard Phillips, Bristi Basu, Zohra Butt, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
March 5, 2022
A Phase I Study Investigating AZD8186, a Potent and Selective Inhibitor of PI3Kβ/δ, in Patients with Advanced Solid Tumors
Atish D Choudhury, Celestia S Higano, Johann S de Bono, et al.
Nature Medicine
|
April 24, 2019
Utility of ctDNA to support patient selection for early phase clinical trials: the TARGET study
Dominic G Rothwell, Mahmood Ayub, Natalie Cook, et al.
Cell Reports. Medicine
|
April 1, 2025
TIMEPOINT, a phase 1 study combining MTL-CEBPA with pembrolizumab, supports the immunomodulatory effect of MTL-CEBPA in solid tumors
Ruth Plummer, Mikael H Sodergren, Rose Hodgson, et al.
Page
of 9
Search research articles
Search
Showing results (81-90 of 88) with videos related to
Sort By:
Page
of 9
You have reached the last page of results.
This site can display upto 88 results.
Nature Cancer
|
February 5, 2022
A biobank of small cell lung cancer CDX models elucidates inter- and intratumoral phenotypic heterogeneity
Kathryn L Simpson, Ruth Stoney, Kristopher K Frese, et al.
Lancet (London, England)
|
August 3, 2024
Molecularly guided therapy versus chemotherapy after disease control in unfavourable cancer of unknown primary (CUPISCO): an open-label, randomised, phase 2 study
Alwin Krämer, Tilmann Bochtler, Chantal Pauli, et al.
European Journal of Cancer (Oxford, England : 1990)
|
October 10, 2022
Real-world outcomes with ipilimumab and nivolumab in advanced melanoma: a multicentre retrospective study
Patricio Serra-Bellver, Judith M Versluis, Honey K Oberoi, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
August 19, 2022
A Phase I Trial of CT900, a Novel α-Folate Receptor-Mediated Thymidylate Synthase Inhibitor, in Patients with Solid Tumors with Expansion Cohorts in Patients with High-Grade Serous Ovarian Cancer
Susana Banerjee, Vasiliki Michalarea, Joo Ern Ang, et al.
British Journal of Cancer
|
November 8, 2025
Experimental Cancer Medicine Centre (ECMC) network proposal for a consensus gene panel for pan-cancer sequencing: a Delphi methodology
Richard Phillips, Bristi Basu, Zohra Butt, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
March 5, 2022
A Phase I Study Investigating AZD8186, a Potent and Selective Inhibitor of PI3Kβ/δ, in Patients with Advanced Solid Tumors
Atish D Choudhury, Celestia S Higano, Johann S de Bono, et al.
Nature Medicine
|
April 24, 2019
Utility of ctDNA to support patient selection for early phase clinical trials: the TARGET study
Dominic G Rothwell, Mahmood Ayub, Natalie Cook, et al.
Cell Reports. Medicine
|
April 1, 2025
TIMEPOINT, a phase 1 study combining MTL-CEBPA with pembrolizumab, supports the immunomodulatory effect of MTL-CEBPA in solid tumors
Ruth Plummer, Mikael H Sodergren, Rose Hodgson, et al.
Page
of 9